Contribution: Industrial Research Assistance Program – Contributions to Firms
Phoenix Molecular Designs Ltd.
$500,000.00
Preclinical Development of the Orally Bioavailable Small Molecule RSK inhibitor PMD-026 for the Treatment of Cancer
FY 2018-19 · 2018-04-01
Summary
Triple-negative breast cancers (TNBC) are one of the most difficult cancers to treat, as they lack the common receptor targets for current breast cancer chemotherapies. TNBC represents 15-25% of all breast cancers, and RSK represents a novel target for TNBC. PMD-026 is a first-in-class RSK inhibitor, and the proposed Project will assess pre-clinical safety of this lead compound in relevant animal models and investigate potential drug-drug interactions, in anticipation of IND submission and human trials.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Vancouver|Vancouver, British Columbia, Canada
Recipient Type
For-profit organization
Business Number
808104087
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2018-04-01 | 2018-19 | $225,000.00 |
| 1 | 2018-04-01 | 2018-19 | $350,000.00 |
| 2 | 2018-04-01 | 2018-19 | $500,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The total amended value is 150,000 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La valeur totale des modifications est de 150 000 dollars.
Agreement End Date
2019-07-31
Agreement Number
904717
Agreement Start Date
2018-04-01
Agreement Title
Preclinical Development of the Orally Bioavailable Small Molecule RSK inhibitor PMD-026 for the Treatment of Cancer
Agreement Title (French)
Développement préclinique de l'inhibiteur PMD-026 biodisponible oralement à petite molécule RSK pour le traitement du cancer
Agreement Type
Contribution
Agreement Value
$500,000.00
Amendment Date
2019-01-11
Amendment Number
2
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Triple-negative breast cancers (TNBC) are one of the most difficult cancers to treat, as they lack the common receptor targets for current breast cancer chemotherapies. TNBC represents 15-25% of all breast cancers, and RSK represents a novel target for TNBC. PMD-026 is a first-in-class RSK inhibitor, and the proposed Project will assess pre-clinical safety of this lead compound in relevant animal models and investigate potential drug-drug interactions, in anticipation of IND submission and human trials.
Description (French)
Les cancers du sein triple-négatif (TNBC) sont l'un des cancers les plus difficiles à traiter, car ils n'ont pas les cibles du récepteur communes pour les chimiothérapies du cancer du sein. TNBC représente de 15 à 25 % de tous les cancers du sein, et RSK représente une nouvelle cible pour TNBC. PMD-026 est un inhibiteur de première classe RSK, et le projet proposé évaluera la sécurité préclinique de ce composé de plomb dans les modèles animaux et étudiera les interactions médicamenteuses possibles, en prévision de soumission IND et les essais humains.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Vancouver Quadra
Federal Riding (French)
Vancouver Quadra
Federal Riding Number
59039
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
808104087
Recipient City
Vancouver|Vancouver
Recipient Country
CA
Recipient Legal Name
Phoenix Molecular Designs Ltd.
Recipient Postal Code
V6R 1E5
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
172-2018-2019-Q1-904717
